Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo for symbol MDGL
Madrigal Pharmaceuticals
MDGL
53
$277.59arrow_drop_up0.20%$0.57

Performance History

Chart placeholder
Key Stats
Open$275.00
Prev. Close$277.01
EPS-23.15
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$4.74B
PE Ratio-
LOWHIGH
Day Range268.07
280.00
52 Week Range119.76
299.98
Ratios
P/B Ratio12.24
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %-26.50%
EBITDA Margin %-
ROE %-88.78%
EPS-23.15

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$878.45
24H (%)arrow_drop_down0.55%
24H ($)-$4.88
MARKET CAP$771.28B
PRICE$497.12
24H (%)arrow_drop_down0.03%
24H ($)-$0.17
MARKET CAP$443.63B
PRICE$145.53
24H (%)arrow_drop_up0.06%
24H ($)$0.09
MARKET CAP$347.62B
PRICE$129.48
24H (%)arrow_drop_up0.08%
24H ($)$0.11
MARKET CAP$318.88B

About Madrigal Pharmaceuticals (MDGL)

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Paul A. Friedman M.D.
Headquarters
West Conshohocken
Employees
92
Exchange
NASDAQ
add Madrigal Pharmaceuticals  to watchlist

Keep an eye on Madrigal Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Madrigal Pharmaceuticals 's (MDGL) price per share?

The current price per share for Madrigal Pharmaceuticals (MDGL) is $277.59. The stock has seen a price change of $0.57 recently, indicating a 0.21% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Madrigal Pharmaceuticals (MDGL)?

For Madrigal Pharmaceuticals (MDGL), the 52-week high is $299.98, which is 8.07% from the current price. The 52-week low is $119.76, the current price is 131.79% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Madrigal Pharmaceuticals (MDGL) a growth stock?

Madrigal Pharmaceuticals (MDGL) has shown an average price growth of 0.41% over the past three years. It has received a score of 93 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Madrigal Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Madrigal Pharmaceuticals (MDGL) stock price performance year to date (YTD)?

As of the latest data, Madrigal Pharmaceuticals (MDGL) has a year-to-date price change of 22.36%. Over the past month, the stock has experienced a price change of 31.11%. Over the last three months, the change has been 2.67%. Over the past six months, the figure is 17.06%. Looking at a longer horizon, the five-year price change stands at 175.72%.

help
Is Madrigal Pharmaceuticals (MDGL) a profitable company?

Madrigal Pharmaceuticals (MDGL) has a net income of -$373.63M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$380.5M. Furthermore, the EBITDA is -$453.63M.

help
What is the market capitalization of Madrigal Pharmaceuticals (MDGL)?

Madrigal Pharmaceuticals (MDGL) has a market capitalization of $4.74B. The average daily trading volume is 811.47K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level